Epstein-Barr virus-related tumor
MONDO:0017342Also known as: EBV-related tumor, EBV-related tumour
2411 clinical trials for this condition and its sub-types, 8 tagged with Epstein-Barr virus-related tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Epstein-Barr virus-related tumor
-
Epstein-Barr virus-associated lymphoproliferative disorder 22 trials · 713 incl. sub-types
11 sub-types
- Hodgkins lymphoma 262 trials · 326 incl. sub-types Sub-types →
- Burkitt lymphoma 221 trials Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Extranodal nasal NK/T cell lymphoma 51 trials
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly 23 trials
- Plasmablastic lymphoma 20 trials
- Primary effusion lymphoma 18 trials
- Lymphomatoid granulomatosis 3 trials · 7 incl. sub-types Sub-types →
- Diffuse large B-cell lymphoma with chronic inflammation 3 trials
- Hydroa vacciniforme-like lymphoma 3 trials
- Systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood 2 trials
-
Epstein-Barr virus-associated carcinoma 2 trials · 214 incl. sub-types
3 sub-types
- Nasopharyngeal carcinoma 211 trials · 212 incl. sub-types Sub-types →
- Epstein-Barr virus-associated gastric carcinoma 1 trial
- Lymphoepithelial-like carcinoma 1 trial
-
Epstein-Barr virus-associated mesenchymal tumor 1 trial · 75 incl. sub-types
3 sub-types
- Leiomyosarcoma 62 trials · 72 incl. sub-types Sub-types →
- Follicular dendritic cell sarcoma 2 trials
- Myopericytoma 0 trials
Most studied deeper sub-types
-
New vaccine aims to stop Virus-Linked cancers in organ transplant patients
Vaccine Recruiting nowThis early-stage trial tests a vaccine called OSU-2131, designed to help the immune system fight Epstein-Barr virus (EBV). EBV can cause cancers in people who have weakened immune systems, such as those awaiting organ transplants. The study includes healthy volunteers and transpl…
Phase 1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Vaccine
Last updated Jul 04, 2026 00:00 UTC
-
New cell therapy targets EBV-Linked cancers in early trial
Disease control Recruiting nowThis early-phase study is testing an experimental cell therapy called EBV-AST for people with Epstein-Barr virus (EBV)-related lymphoproliferative disorders, including certain blood cancers and post-transplant complications. About 18 adults will receive up to 3 infusions of the t…
Phase 1/2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Engineered immune cells take aim at stubborn lymphoma
Disease control Recruiting nowThis early-phase trial tests whether a personalized immune cell therapy called anti-EBV TCR-T cells is safe for people with relapsed or refractory EBV-positive lymphoma who have a specific genetic marker (HLA-A11:01). The treatment involves taking a patient's own T cells, enginee…
Early phase 1 • Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Mapping the immune System's fight against certain cancers
Knowledge-focused Recruiting nowThis study looks at how T cells (a type of immune cell) respond to liver cancer and cancers linked to Epstein-Barr virus (EBV) and human papillomavirus (HPV). About 105 participants will give blood and tissue samples once. Researchers will analyze these samples to identify cancer…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC